Replies to post #5247 on Dendreon Corp fka DNDNQ

[rancherho]

Wall:

FWIW I also minimized the competitive threat of CEGE's GVAX to DNDN's Provenge in 11/05 before all the events of the last 12 months. See:http://www1.investorvillage.com/smbd.asp?mb=971&mn=11568&pt=msg&mid=770730

As more data has been made available, however, I have moderated those views. BTW, the CEGE CEO has acknowledged that any of its trials can be stopped for safety concerns, which presumably would include more fatalities in the experimental arm than the control arm, as recently occurred with NOVC's calcitrol. The context was that he was referring to stopping Vital 1 for futility because of lack of efficacy at the interim, which he said will not occur.